Skip to main content
. 2009 May 4;114(2):261–263. doi: 10.1182/blood-2008-09-180604

Figure 1.

Figure 1

Platelet aggregation induced by different agonists in patients with CML in chronic phase receiving therapy with different tyrosine kinase inhibitors. Dasatinib was more frequently associated with epinephrine-induced platelet aggregation defects compared with imatinib, nilotinib, and bosutinib (P < .001, one-way ANOVA) and with AA-induced platelet aggregation defects compared with nilotinib and bosutinib (P < .001, t test), but not with imatinib (P = .55, t test). Error bars represent SD.